Evidence map›Paper›PMID 29513618›Full record

ReviewJournal of dental research2018

Liquid Biopsy in Head and Neck Cancer: Promises and Challenges.

T Nonaka, D T W Wong

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of dental research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Journal of oral microbiology · 2025
    Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Liquid biopsy for diagnostic and prognostic evaluation of melanoma.Frontiers in cell and developmental biology · 2024
    Review
  19. Review
  20. Saliva diagnostics: Salivaomics, saliva exosomics, and saliva liquid biopsy.Journal of the American Dental Association (1939) · 2023
    Review

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

T Nonaka1 Center for Oral/Head and Neck Oncology Research, School of Dentistry, University of California, Los Angeles, CA, USA.ORCID 0000-0002-9183-4734
D T W Wong1 Center for Oral/Head and Neck Oncology Research, School of Dentistry, University of California, Los Angeles, CA, USA.

Funding

Clinical Utility of Salivary ExRNA Biomarkers for Gastric Cancer DetectionUH3TR000923 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WONG, DAVID T · 2015 to 2017
$2.7M
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC PatientsUH3CA206126 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHIA, DAVID S., SOO HOO, GUY · 2019 to 2021
$1.2M
Clinical Utility of Salivary ExRNA Biomarkers for Gastric Cancer DetectionUH2TR000923 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WONG, DAVID T · 2013 to 2014
$996k
UCLA Dentist-Scientist and Oral Health-Researcher Training ProgramR90DE023057 · NIDCR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WONG, DAVID T · 2012 to 2016
$416k
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC PatientsUH2CA206126 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHIA, DAVID S., DAS, KINGSHUK · 2017 to 2018
$368k
Immunomodulatory effects of cytomegalovirus-induced salivary soluble form of NHC class IR03DE027759 · NIDCR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NONAKA, TAICHIRO · 2018 to 2019
$311k
NCATS NIH HHS UH2 TR000923NCATS NIH HHS UH3 TR000923NCI NIH HHS UH2 CA206126NCI NIH HHS UH3 CA206126NIDCR NIH HHS R03 DE027759NIDCR NIH HHS R90 DE023057
6 · The paper itself

Abstract

Head and neck cancer is the sixth most common cancer worldwide. It remains one of the leading causes of death, and its early detection is crucial. Liquid biopsy has emerged as a promising tool for detecting and monitoring the disease status of patients with early and advanced cancers. Circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomal miRNAs have received enormous attention because of their apparent clinical implications. Analyses of these circulating biomarkers have paved the way for novel therapeutic approaches and precision medicine. A growing number of reports have implicated the use of circulating biomarkers for detection, treatment planning, response monitoring, and prognosis assessment. Although these new biomarkers can provide a wide range of possible clinical applications, no validated circulating biomarkers have yet been integrated into clinical practice for head and neck cancer. In this review, we summarize the current knowledge of circulating biomarkers in this field, focusing on their feasibility, limitations, and key areas of clinical applications. We also highlight recent advances in salivary diagnostics and their potential application in head and neck cancer.

Indexed as

Liquid BiopsyBiomarkers, TumorDNA, NeoplasmHead and Neck NeoplasmsHumansSalivaBiomarkers, TumorDNA, Neoplasmbiomarkercirculating tumor cellcirculating tumor DNAexosomal miRNAsaliva-exosomicssalivary diagnostics

Identifiers

PMID29513618
PMCPMC5960882

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.